Fast Track Group FTRK 深 沪
已收盘 03-27 16:00:00 美东时间
0.3833
-0.072
-15.78%
华盛通- 最 高0.532
- 今 开0.4402
- 成交量 1.58万股
- 最 低 0.3833
- 昨 收 0.4551
- 总市值 836.07万
- 52周最高 9.69
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 0.2916
- 委 比 81.82%
- 总股本 2181.25万
- 历史最高 9.69
- 量 比 0.50
- 振 幅 32.67%
- 历史最低 0.2916
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iterum Therapeutics Announces Filing of Winding Up Petition
Iterum Therapeutics plc has filed a petition in Ireland's High Court to wind up its company due to limited cash resources, inability to raise additional capital, failure to regain NASDAQ listing compliance, and high operational expenses. The company may withdraw its drug ORLYNVAH™ from the U.S. market. The liquidation process is expected to result in dissolution of the company and its subsidiaries.
03-27 13:25
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics announces FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic designed to cross the blood-brain barrier for Hunter syndrome, a rare genetic disorder. AVLAYAH is an enzyme replacement therapy indicated for pediatric patients with neurologic manifestations of Hunter syndrome. It is the first treatment in nearly 20 years for this condition and the first in a new class of biotherapeutics ...
03-25 15:50
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.
03-25 01:58
Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial
Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
03-24 19:14
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000 Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%. FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was
03-23 20:38
Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
03-19 18:05
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
<p>Acrivon Therapeutics reported positive clinical data for ACR-368 in serous endometrial cancer (EC), showing a confirmed overall response rate (cORR) of 52%. The company expanded its Phase 2b study with additional arms targeting broader EC patient populations. ACR-2316, another compound, demonstrated promising activity in lung cancer. The company has strong financials with $118.6 million in cash, supporting operations into 2027.</p>
03-19 11:21
Meta Is Launching A Creator Fast Track Program On Facebook
https://about.fb.com/news/2026/03/creator-fast-track-grow-your-audience-earn-money-on-facebook/
03-19 00:03
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
ProMIS Neurosciences将参加2026年3月17-21日在丹麦哥本哈根举行的AD/PD™ 2026会议，展示两项科学海报，涉及其专有平台在治疗神经退行性疾病中的最新研究。本次会议将突出公司利用EpiSelect™平台开发选择性靶向有毒错误折叠蛋白的治疗方法的成果。此外，公司还将讨论其针对阿尔茨海默病的领先候选药物PMN310的最新进展。
03-18 12:00
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Zymeworks Inc.'s partner, Jazz Pharmaceuticals, will present four abstracts on zanidatamab at the AACR Annual Meeting, highlighting its potential in treating HER2-expressing cancers. Key findings include significant tumor reduction and manageable safety in early-stage HER2+ breast cancer, insights into its unique HER2 biology, and its efficacy post-T-DXd progression. Additional studies explore its utility across solid tumors and adaptive trial de...
03-18 11:46
